This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Lynn D. Kramer, MD

Arch Neurol. 1995;52(1):101-102.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE THERAPY of cysticercosis can be divided into two general categories: disease-directed therapy or symptomatic therapy. The disease-directed therapies include the cysticidal antihelminthic drugs (albendazole and praziquantel), surgical cyst extirpation, and observation without intervention. Symptomatic therapies include corticosteroids for intracranial edema and inflammation, antiepileptic drugs for secondarily acquired epilepsy, surgical procedures such as shunts, and various medications for headaches. Unfortunately, there have been no well-controlled trials to evaluate or compare any of these therapies; therefore, controversy persists.

The life cycle of the parasite, Taenia solium, may include man as either the intermediate host—although swine commonly occupy this niche—or the definite host.¹ Antihelminthic drugs have proven effective in eliminating the intestinal adult tapeworm, when man serves the role of definitive host; no further remarks will be made concerning this indication for therapy. When man serves as intermediate host, the hexacanth embryo undergoes hematogenous transport until it comes to rest, . . . [Full Text PDF of this Article]

Author Affiliations
From the R. W. Johnson Pharmaceutical Research Institute, Spring House, Pa.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?